Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1974 Jun;5(6):611–616. doi: 10.1128/aac.5.6.611

Pharmacokinetics of Tobramycin in Patients with Stable Renal Impairment, Patients Undergoing Peritoneal Dialysis, and Patients on Chronic Hemodialysis

Gabriel Jaffe 1, Burt R Meyers 1, Shalom Z Hirschman 1
PMCID: PMC429023  PMID: 15825414

Abstract

The pharmacokinetics of tobramycin were studied in five patients with stable renal impairment, four patients requiring peritoneal dialysis, and four patients on chronic hemodialysis. The half-life of the drug varied with the level of the serum creatinine in the first group of patients, and the average volume of distribution was 15 liters. Only 49% of the administered dose of tobramycin was recovered during 36 h of peritoneal dialysis. The average clearance of tobramycin during hemodialysis was 49.1 ml/min, and 51.5% of the administered dose was recovered during a 6-h dialysis.

Full text

PDF
616

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Cutler R. E., Gyselynck A. M., Fleet W. P., Forrey A. W. Correlation of serum creatinine concentration and gentamicin half-life. JAMA. 1972 Feb 21;219(8):1037–1041. [PubMed] [Google Scholar]
  2. Del Bene V. E., Farrar W. E., Jr Tobramycin: in vitro activity and comparison with kanamycin and gentamicin. Antimicrob Agents Chemother. 1972 Apr;1(4):340–342. doi: 10.1128/aac.1.4.340. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Dienstag J., Neu H. C. In vitro studies of tobramycin, an aminoglycoside antibiotic. Antimicrob Agents Chemother. 1972 Jan;1(1):41–45. doi: 10.1128/aac.1.1.41. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Gibaldi M., Perrier D. Drug distribution and renal failure. J Clin Pharmacol New Drugs. 1972 May-Jun;12(5):201–204. doi: 10.1002/j.1552-4604.1972.tb00162.x. [DOI] [PubMed] [Google Scholar]
  5. Jaffe G., Ravreby W., Meyers B. R., Hirschman S. Z. Clinical study of the use of the new aminoglycoside tobramycin for therapy of infections due to gram-negative bacteria. Antimicrob Agents Chemother. 1974 Jan;5(1):75–81. doi: 10.1128/aac.5.1.75. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Lockwood W. R., Bower J. D. Tobramycin and gentamicin concentrations in the serum of normal and anephric patients. Antimicrob Agents Chemother. 1973 Jan;3(1):125–129. doi: 10.1128/aac.3.1.125. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Meyers B. R., Hirschman S. Z. Pharmacologic studies on tobramycin and comparison with gentamicin. J Clin Pharmacol New Drugs. 1972 Aug-Sep;12(8):321–324. doi: 10.1002/j.1552-4604.1972.tb00174.x. [DOI] [PubMed] [Google Scholar]
  8. Meyers B. R., Hirschman S. Z. Tobramycin: in vitro antibacterial spectrum of a new aminoglycoside. J Clin Pharmacol New Drugs. 1972 Aug-Sep;12(8):313–320. doi: 10.1002/j.1552-4604.1972.tb00173.x. [DOI] [PubMed] [Google Scholar]
  9. Naber K. G., Westenfelder S. R., Madsen P. O. Pharmacokinetics of the aminoglycoside antibiotic tobramycin in humans. Antimicrob Agents Chemother. 1973 Apr;3(4):469–473. doi: 10.1128/aac.3.4.469. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Regamey C., Gordon R. C., Kirby W. M. Comparative pharmacokinetics of tobramycin and gentamicin. Clin Pharmacol Ther. 1973 May-Jun;14(3):396–403. doi: 10.1002/cpt1973143396. [DOI] [PubMed] [Google Scholar]
  11. Simon V. K., Mösinger E. U., Malerczy V. Pharmacokinetic studies of tobramycin and gentamicin. Antimicrob Agents Chemother. 1973 Apr;3(4):445–450. doi: 10.1128/aac.3.4.445. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Weinstein A. J., Karchmer A. W., Moellering R. C., Jr Tobramycin concentrations during peritoneal dialysis. Antimicrob Agents Chemother. 1973 Oct;4(4):432–434. doi: 10.1128/aac.4.4.432. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES